Cyclandelate | CAS#456-59-7 | Vasodilator

MedKoo Cat#: 317569 | Name: Cyclandelate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cyclandelate is a direct-acting smooth muscle relaxant vasodilator used in the treatment of claudication, arteriosclerosis and Raynaud's disease. It is also used to treat nighttime leg cramps, and has been investigated for its effect against migraine. It is orally administered.

Chemical Structure

Cyclandelate

CAS#456-59-7

Theoretical Analysis

MedKoo Cat#: 317569

Name: Cyclandelate

CAS#: 456-59-7

Chemical Formula: C17H24O3

Exact Mass: 276.1725

Molecular Weight: 276.37

Elemental Analysis: C, 73.88; H, 8.75; O, 17.37

Price and Availability

Size	Price	Availability	Quantity
1g	USD 250.00	2 Weeks
5g	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Cyclandelate; Cyclospasmol; Capilan; Ciclospasmol; Spasmocyclon; Spasmocyclone;

IUPAC/Chemical Name

(3,3,5-trimethylcyclohexyl) 2-hydroxy-2-phenylacetate

InChi Key

WZHCOOQXZCIUNC-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3

SMILES Code

CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O

Appearance

White to off-white solid powder.

Purity

>94% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 276.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Diener HC, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. Cephalalgia. 2001 Feb;21(1):66-70. PubMed PMID: 11298666. 2: Weyer G, Eul A, Milde K, Wierich W, Herrmann WM. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study. Pharmacopsychiatry. 2000 May;33(3):89-97. PubMed PMID: 10855459. 3: Siniatchkin M, Gerber WD, Vein A. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study. Funct Neurol. 1998 Jan-Mar;13(1):47-56. PubMed PMID: 9584874. 4: Hester TO, Theilman G, Green W, Jones RO. Cyclandelate in the management of tinnitus: a randomized, placebo-controlled study. Otolaryngol Head Neck Surg. 1998 Mar;118(3 Pt 1):329-32. PubMed PMID: 9527112. 5: Schellenberg R, Todorova A, Wedekind W, Schober F, Dimpfel W. Pathophysiology and psychopharmacology of dementia--a new study design. 2. Cyclandelate treatment--a placebo-controlled double-blind clinical trial. Neuropsychobiology. 1997;35(3):132-42. PubMed PMID: 9170118. 6: Diener HC, Föh M, Iaccarino C, Wessely P, Isler H, Strenge H, Fischer M, Wedekind W, Taneri Z. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group. Cephalalgia. 1996 Oct;16(6):441-7. PubMed PMID: 8902255. 7: Gerber WD, Schellenberg R, Thom M, Haufe C, Bölsche F, Wedekind W, Niederberger U, Soyka D. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study. Funct Neurol. 1995 Jan-Feb;10(1):27-35. PubMed PMID: 7649498. 8: Dimpfel W, Schober F, Wedekind W, Kleinbloesem C, Coors C. [Evidence of a pharmacokinetic-pharmacodynamic relationship between pharmaco-EEG in healthy subjects after administration of cyclandelate]. Arzneimittelforschung. 1994 Sep;44(9):999-1004. German. PubMed PMID: 7986255. 9: White DA, Heffron F, Knight D, Salter AM. The effects of two acylcoenzyme A: cholesterol acyltransferase (ACAT) inhibitors, cyclandelate and a non-hydrolysable ether analogue, benzyl3,3,5-trimethylcyclohexanol on low density lipoprotein metabolism in macrophages and hepatocytes. Biochem Pharmacol. 1994 Aug 30;48(5):915-22. PubMed PMID: 8093104. 10: Kitajima A, Yoshii K, Komatsu H, Ishimitsu S, Okada S. [The Cyclandelate Reference Standard (Control 931) of the National Institute of Health Sciences]. Eisei Shikenjo Hokoku. 1994;(112):185-7. Japanese. PubMed PMID: 8854927.